Posted: 19 December 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is pleased to announce that it has successfully raised well over its target AU$15M…
Posted: 19 December 2024 Developing advanced rapid diagnostics for the mpox virus and consolidating global expertise in human organoids to aid pandemic therapeutic research are just two of the innovative projects being funded through the Melbourne-Calgary Collaborative Seed…
Posted: 19 December 2024 Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today announces a positive development regarding its DEP® SN38 (DEP®…
Posted: 18 December 2024 Australian researchers have discovered a potential new lifeline for the tiniest and most vulnerable newborns. Scientists at Monash Children’s Hospital have successfully collected and reinfused umbilical cord blood cells in extremely premature babies, offering…
Posted: 18 December 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, is pleased to announce that it has been awarded a US$300K G-Rex grant to…
Posted: 17 December 2024 4DMedical (ASX: 4DX) has been awarded a contract with US-based Imaging Partners of Orange County (IPOC) to provide computed tomography (CT) scans for lung ventilation (LVAS) and lung density (LDAf) analysis. The contract – the…
Posted: 17 December 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has successfully completed stage 1 of its development program for an exosome therapeutic for breast cancer. In this in vitro proof-ofconcept (POC) study,…
Posted: 16 December 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003…
Posted: 11 December 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report updated data from Company’s ongoing Phase 2a clinical trial. This trial is investigating the Company’s FAK inhibitor narmafotinib in combination with…
Posted: 10 December 2024 Medicines Development for Global Health (MDGH) announced today that the Ghana Food and Drugs Authority (FDA) has approved the marketing authorisation application for moxidectin 2 mg oral tablets for the treatment of river blindness (onchocerciasis)…
Posted: 10 December 2024 A US$1.5 million gift from the Colossal Foundation, a non-profit organisation established by Colossal Biosciences, will help researchers in the Faculty of Science develop new approaches to the conservation of bird species in Australia and…
Posted: 10 December 2024 Breakthrough Victoria is investing $2 million in Umps Health, a Victorian company developing sensors and AI to enable proactive aged care at home. The Umps Link, a smart home platform, is the product of…